{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Number of Participants with NCI CTCAE Version 4.0 Adverse Events related to study treatment greater than or equal to Grade 3","groups":[{"description":"Participants who received cytoreductive chemotherapy followed by infusion of lentivirus-mediated genetically engineered NY-ESO-1ᶜ²⁵⁹T (Target dose: 1-10 billion cells)","id":"OG000","title":"NY-ESO-1ᶜ²⁵⁹T Cells Administered IV"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received NY-ESO-1ᶜ²⁵⁹T","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Adverse Events Related to Study Treatment","type":"PRIMARY","unitOfMeasure":"Participants"}